Clinical Trials Directory

Trials / Completed

CompletedNCT02724449

A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
16 (actual)
Sponsor
Solventum US LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to obtain information concerning the safety and effective use of a protective barrier film in patients experiencing severe incontinence associated dermatitis.

Detailed description

This is an open label, non randomized prospective case series evaluating 3M Cavilon Advanced Barrier Film for the treatment of severe incontinence associated dermatitis (IAD) in the presence or absence of continued fecal or fecal and urinary incontinence. The product will be applied twice a week for a maximum duration of 3 weeks. Subjects will be followed twice a week until healing, for a maximum of 3 weeks or earlier, if discharged from the facility. During the study period, the frequency and intensity of their incontinence will be monitored, twice a week photographic documentation and IAD site assessments will be completed.

Conditions

Interventions

TypeNameDescription
DEVICECavilon Advanced Barrier FilmCavilon Advanced Barrier Fim's application applied twice a week

Timeline

Start date
2014-08-01
Primary completion
2015-02-01
Completion
2015-02-01
First posted
2016-03-31
Last updated
2024-12-17
Results posted
2017-06-09

Source: ClinicalTrials.gov record NCT02724449. Inclusion in this directory is not an endorsement.